Patient preference for once-monthly ibandronate versus once-weekly alendronate in a randomized, open-label, cross-over trial: the Boniva Alendronate Trial in Osteoporosis (BALTO)

By Emkey Ronald   Koltun William   Beusterien Kathleen   Seidman Larry   Kivitz Alan   Devas Vipul   Masanauskaite Daiva  

Current Medical Research and Opinion, Vol. 21, Iss. 12, 2005-12 ,pp. : 1895-1903

Informa Healthcare

Access to resources Recommend Favorite

Persistence across weekly and monthly bisphosphonates: analysis of US retail pharmacy prescription refills

By Weiss Thomas W.   Henderson Scott C.   McHorney Colleen A.   Cramer Joyce A.  

Current Medical Research and Opinion, Vol. 23, Iss. 9, 2007-09 ,pp. : 2193-2203

Informa Healthcare

Access to resources Recommend Favorite

Update on monthly oral bisphosphonate therapy for the treatment of osteoporosis: focus on ibandronate 150 mg and risedronate 150 mg

By Epstein S.   Jeglitsch M.   McCloskey E.  

Current Medical Research and Opinion, Vol. 25, Iss. 12, 2009-12 ,pp. : 2951-2960

Informa Healthcare

Access to resources Recommend Favorite

Once-monthly oral ibandronate compared with weekly oral alendronate in postmenopausal osteoporosis: results from the head-to-head MOTION study

By Miller Paul D.   Epstein Sol   Sedarati Farhad   Reginster Jean-Yves  

Current Medical Research and Opinion, Vol. 24, Iss. 1, 2008-01 ,pp. : 207-213

Informa Healthcare

Access to resources Recommend Favorite

In vitro disintegration studies of weekly generic and branded risedronate sodium formulations available in Canada

By Walker A.D.   Adachi J.D.  

Current Medical Research and Opinion, Vol. 27, Iss. 9, 2011-09 ,pp. : 1749-1754

Informa Healthcare

Access to resources Recommend Favorite